A Multi-center, Open-label Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

This is a Multi-center, Open-label Study on the Efficacy and Safety of Multiple Treatments with Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines. The study has been designed to evaluate the long-term safety, tolerability, efficacy , maintain time and immunogenicity of multiple treatments with Recombinant Botulinum Toxin Type A for Injection (YY001) in the treatment of moderate to severe glabellar lines.

Start Date19 Mar 2024

Sponsor / Collaborator

Claruvis Pharmaceutical Co.

NCT06228846 / Active, not recruitingPhase 1

An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients With Advanced Solid Tumors

The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.

Start Date14 Jul 2022

Sponsor / Collaborator

Shanghai Yuyao Biotechnology Co., Ltd.

CTR20221559 / Active, not recruitingPhase 1

评价YY001治疗晚期实体瘤患者的安全性、耐受性、药代动力学特征的开放性I期临床研究

[Translation] An open-label phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of YY001 in the treatment of patients with advanced solid tumors

主要目的：评价YY001治疗晚期实体瘤患者的安全性、耐受性，观察可能出现的剂量限制性毒性（DLT）及最大耐受剂量（MTD）或推荐II期临床给药剂量（RP2D）。次要目的：评价YY001在晚期实体瘤患者中的药代动力学（PK）特征和抗肿瘤活性。探索性目的：初步评价生物标志物与疗效之间的关系。

[Translation]

Primary objective: To evaluate the safety and tolerability of YY001 in the treatment of patients with advanced solid tumors, and to observe possible dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D). Secondary objective: To evaluate the pharmacokinetic (PK) characteristics and antitumor activity of YY001 in patients with advanced solid tumors. Exploratory objective: To preliminarily evaluate the relationship between biomarkers and efficacy.

Start Date14 Jul 2022

Sponsor / Collaborator

Shanghai Yuyao Biotechnology Co., Ltd.

100 Clinical Results associated with YY-001

100 Translational Medicine associated with YY-001

100 Patents (Medical) associated with YY-001

Literatures (Medical) associated with YY-001

01 Jul 2024·Genes & Diseases

Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4

Article

Author: Hu, Shixiu ; Tang, Kefu ; He, Yundong ; Sun, Jialiang ; Hu, Pan ; Guo, Mengmeng ; Li, Jing ; Liu, Mingyao ; Xie, Jiayi ; Lu, Weiqiang ; Yi, Zhengfang ; Peng, Shihong ; Liu, Huirong

Gastric cancer is highly prevalent among digestive tract tumors. Due to the intricate nature of the gastric cancer immune microenvironment, there is currently no effective treatment available for advanced gastric cancer. However, there is promising potential for immunotherapy targeting the prostaglandin E2 receptor subtype 4 (EP4) in gastric cancer. In our previous study, we identified a novel small molecule EP4 receptor antagonist called YY001. Treatment with YY001 alone demonstrated a significant reduction in gastric cancer growth and inhibited tumor metastasis to the lungs in a mouse model. Furthermore, administration of YY001 stimulated a robust immune response within the tumor microenvironment, characterized by increased infiltration of antigen-presenting cells, T cells, and M1 macrophages. Additionally, our research revealed that YY001 exhibited remarkable synergistic effects when combined with the PD-1 antibody and the clinically targeted drug apatinib, rather than fluorouracil. These findings suggest that YY001 holds great promise as a potential therapeutic strategy for gastric cancer, whether used as a standalone treatment or in combination with other drugs.

01 Jan 2021·Ying yong sheng tai xue bao = The journal of applied ecology

[Effects of leaf extracts of Amorpha fruticosa on seed germination and seedling growth of Amygdalus pedunculata].

Article

Author: DI, Long ; Wang, Huai-Biao ; Wang, Jin-Xin ; Ma, Xu ; Wang, Yu-Bao ; Zhang, Yu-Yu ; Wang, Xiu-Qing

Amorpha fruticosa and Amygdalus pedunculata are common plant species used for greening construction in arid and semi-arid region of Northwest China. In order to explore the feasibility of greening construction and ecological restoration by A. fruticose with A. pedunculata, we exami-ned the allelopathic effects of five concentrations of aqueous leaf extracts of A. fruticosa (0.025, 0.05, 0.10, 0.15 and 0.20 g·mL^-1) on eight A. pedunculata varieties (YY₁, YY₃, YY₄, YY₅, YY₆, SM₆, SM₇ and SM₈), using the methods of paper-petri dish and soilless culture. The results showed that when the concentration of A. fruticosa leaf extracts were 0.025 and 0.05 g·mL^-1, the seed germination and seedling growth of YY₁ and SM₆ were significantly better than other varieties. With increasing concentration of A. fruticosa leaf extracts, the catalase activity of A. pedunculata seedlings first increased and then decreased. The activities of peroxidase and superoxide dismutase, and the contents of soluble protein and chlorophyll showed a downward trend, while the contents of malondialdehyde and soluble sugar and the permeability of cell membrane gradually increased. Results of the principal component and cluster analysis showed that the growth potential of A. pedunculata decreased with the order of YY₁, SM₆, SM₈, SM₇, YY₆, YY₃, YY₅ and YY₄ under the allelopathic effect of A. fruticose. In conclusion, the artificial collocation and mixed planting of low-density of A. fruticosa with YY₁ and SM₆ were beneficial to seed germination and seedling growth of A. pedunculata.

01 Jul 2020·Cell Biology InternationalQ4 · BIOLOGY

Yin Yang‐1 suppresses CD40 ligand‐CD40 signaling‐mediated anti‐inflammatory cytokine interleukin‐10 expression in pulmonary adventitial fibroblasts by promoting histone H3 tri‐methylation at lysine 27 modification on interleukin‐10 promoter

Q4 · BIOLOGY

Article

Author: Yang, Jin‐Xiu ; Xu, Yi‐Fei ; Pan, Yan‐Yun ; Mao, Wei

AbstractDuring the pathogenesis of early pulmonary arterial hypertension (PAH), pulmonary arterial adventitial fibroblast act as an initiator and mediator of inflammatory processes that predispose vessel walls to excessive vasoconstriction and pathogenic vascular remodeling. Emerging studies report that Yin Yang‐1 (YY‐1) plays important roles in inflammatory response and vascular injury. Our recent study finds that activation of CD40 ligand (CD40L)–CD40 signaling promotes pro‐inflammatory phenotype of pulmonary adventitial fibroblasts. However, whether YY‐1 is involved in CD40L–CD40 signaling‐triggered inflammatory response in pulmonary adventitial fibroblasts and its underlying mechanism is still unclear. Here, we show that soluble CD40L (sCD40L) stimulation promotes YY‐1 protein expression and suppresses anti‐inflammatory cytokine, interleukin 10 (IL‐10) expression in pulmonary adventitial fibroblasts, while YY‐1 knockdown prevents sCD40L‐mediated reduction of IL‐10 expression via enhancing IL‐10 gene transactivation. Further, we find that sCD40L stimulation significantly increases histone H3 tri‐methylation at lysine 27 (H3K27me3) modification on IL‐10 promoter in pulmonary adventitial fibroblasts, and YY‐1 knockdown prevents the effect of sCD40L on IL‐10 promoter by reducing the interaction with enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, binding to IL‐10 promoter. Moreover, we find that sCD40L stimulation promotes YY‐1 protein, but not messenger RNA (mRNA) expression, via decreasing N6‐methyladenosine methylation on YY‐1 mRNA to suppress YTHDF2‐medicated mRNA decay. Overall, this in‐depth study shows that the activation of CD40L‐CD40 signaling upregulates YY‐1 protein expression in pulmonary adventitial fibroblasts, which results in increasing YY‐1 and EZH2 binding to the IL‐10 promoter region to enhance H3K27me3 modification, eventually leading to suppression of IL‐10 transactivation. This study first uncovers the roles of YY‐1 on CD40L‐CD40 signaling‐triggered inflammatory response in pulmonary adventitial fibroblasts.

100 Deals associated with YY-001

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Colonic Cancer	Phase 2	-	Shanghai Yuyao Biotechnology Co., Ltd.	-
Prostatic Cancer	Phase 2	-	Shanghai Yuyao Biotechnology Co., Ltd.	-
Stomach Cancer	Phase 2	-	Shanghai Yuyao Biotechnology Co., Ltd.	-
Advanced Malignant Solid Neoplasm	Phase 1	CN	Shanghai Yuyao Biotechnology Co., Ltd.	14 Jul 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06228846 (phase I study, ASCO2024)	Phase 1	Advanced Malignant Solid Neoplasm	16	YY001 100mg	(obokehakdw) = qvfjhabtpj khwtpubsgk (itsmnniwil, 4.01 - -) View more	Positive	24 May 2024
				YY001 200mg	(obokehakdw) = nqroqvgsdd khwtpubsgk (itsmnniwil, 4.01 - -) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

YY-001

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation